Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Methylprednisolone in Idiopathic Pulmonary Fibrosis: NCT05842681 Clinical Landscape Report 2026
15 October 2026
NCT05842681 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pegargiminase in Metabolic Dysfunction Associated Steatohepatitis: NCT05842512 Clinical Landscape Report 2026
15 October 2026
NCT05842512 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Clonidine Hydrochloride in Vaso-occlusive crisis: NCT05848531 Clinical Landscape Report 2026
15 October 2026
NCT05848531 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Salbutamol sulfate in Amyotrophic Lateral Sclerosis: NCT05860244 Clinical Landscape Report 2026
15 October 2026
NCT05860244 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NB-4746 in Neurodegenerative Diseases: ACTRN12623000476639 Clinical Landscape Report 2026
15 October 2026
ACTRN12623000476639 clinical landscape for Neurodegenerative Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Epeleuton in Anemia, Sickle Cell: NCT05861453 Clinical Landscape Report 2026
15 October 2026
NCT05861453 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ION-455 in Metabolic Dysfunction Associated Steatohepatitis: NCT05864391 Clinical Landscape Report 2026
15 October 2026
NCT05864391 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Edaravone in Amyotrophic Lateral Sclerosis: NCT05866926 Clinical Landscape Report 2026
15 October 2026
NCT05866926 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rituximab in Myasthenia Gravis: NCT05868837 Clinical Landscape Report 2026
15 October 2026
NCT05868837 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efinopegdutide in Metabolic Dysfunction Associated Steatohepatitis: NCT05877547 Clinical Landscape Report 2026
15 October 2026
NCT05877547 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Icomidocholic acid in Metabolic Dysfunction Associated Steatohepatitis: NCT05874336 Clinical Landscape Report 2026
15 October 2026
NCT05874336 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
9MW3811 in Idiopathic Pulmonary Fibrosis: NCT05912049 Clinical Landscape Report 2026
15 October 2026
NCT05912049 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.